Developer docs
API playgroundTry for free, no card

Search company profiles

Ventus Therapeutics

Full company profile

uuid0002oo6

Namestring
Ventus Therapeutics
Legal namestring
Ventus Therapeutics, Inc.
Websiteurl
ventustx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ventus Therapeutics is a privately held, clinical-stage biopharmaceutical company developing small-molecule therapeutics that target innate immune system drivers of disease, specifically the cGAS, NLRP3, and caspase-4/5 pathways, across autoimmune, inflammatory, and neurological indications. The company was founded in 2020 and is headquartered in Waltham, Massachusetts with an additional research and operations footprint in Saint-Laurent (Montreal), Quebec. Its pipeline comprises VENT-03 (a first-in-class oral cGAS inhibitor in Phase 2 for lupus, with expansion plans into broader immunology and cardiometabolic disease), VENT-02 (a brain-penetrant oral NLRP3 inhibitor in Phase 2 for Parkinson's disease), VENT-01 (a systemic NLRP3 inhibitor in Phase 1, partnered with Novo Nordisk), and VENT-04 (a first-in-class allosteric caspase-4/5 inhibitor in IND-enabling studies for IBD, hidradenitis suppurativa, severe asthma, and COPD).

Discovery is powered by the proprietary ReSOLVE® platform, which combines AI/ML with protein science, structural biology, and biophysics to model full protein conformations, identify druggable pockets, characterize dynamic water networks, and generate Hydrocophore® blueprints for rapid virtual screening of billions of compounds. The platform has produced clinically validated outputs: VENT-02 demonstrated 100% IL-1β inhibition in an ex vivo whole-blood challenge assay, broad therapeutic index, and high brain penetration; VENT-03 completed Phase 1 with robust target engagement and once-daily dosing; and a $150,000 grant from The Michael J. Fox Foundation supports an NLRP3 PET tracer diagnostic program.

Ventus operates a capital-light business model with no commercial products. Revenue is generated through collaboration and licensing economics: the company has raised approximately $290 million across Series A, B, and C financings from Versant Ventures, SoftBank Vision Fund 2, RA Capital Management, GV, a16z, and others, and has secured two major strategic partnerships — an exclusive license to Novo Nordisk for systemic NLRP3 inhibitors (September 2022) and a multi-year discovery collaboration with Genentech (October 2025) carrying potential milestones exceeding $460 million plus tiered royalties. Partners lead downstream clinical development and commercialization, allowing Ventus to remain a focused, platform- and early-clinical-stage organization of 11–50 employees.

Short descriptiontext

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small-molecule drugs targeting cGAS, NLRP3, and caspase-4/5 pathways for patients with autoimmune, inflammatory, and neurological diseases, powered by its proprietary ReSOLVE® AI/ML-enabled discovery platform and partnered with Novo Nordisk and Genentech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, drug discovery platform, autoimmune disease therapeutics, inflammatory disease treatment, biopharmaceutical development
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Small Molecule Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration and License Agreement Revenue
TypeLicensing Royalties
Description

Ventus receives upfront payments, preclinical, development, and commercial milestones exceeding $460 million plus tiered royalties on net sales from Genentech collaboration. The company also has a license agreement with Novo Nordisk for NLRP3 inhibitors.

ventustx.com
2Partnered Program Development
TypeLicensing Royalties
Description

VENT-01 is partnered with Novo Nordisk under exclusive development and license agreement. Ventus nominates development candidates which are then developed and commercialized by partners.

ventustx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of differentiated small molecule therapeutics targeting biologically validated but previously undruggable drug targets in innate immunity. Its lead candidates include VENT-03 (cGAS inhibitor, Phase 2 for lupus), VENT-02 (NLRP3 inhibitor, Phase 2 for Parkinson's disease), VENT-04 (caspase-4/5 inhibitor, preclinical), and VENT-01 (systemic NLRP3 inhibitor partnered with Novo Nordisk). The company monetizes through upfront payments, development milestones, and royalties via partnerships with Genentech and Novo Nordisk, using its proprietary ReSOLVE® platform for discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • VENT-02 demonstrated 100% inhibition of IL-1β in blood in ex vivo whole blood challenge assay
+2 more records
Product overview1 text field

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of differentiated small molecule therapeutics targeting biologically validated but previously considered undruggable drug targets in immunology, inflammation, and neurology. The company's portfolio includes: VENT-03 (first-in-class cGAS inhibitor in Phase 2 for lupus), VENT-02 (brain-penetrant NLRP3 inhibitor in Phase 2 for Parkinson's disease), VENT-04 (first-in-class caspase-4/5 inhibitor in preclinical development for IBD, HS, asthma, and COPD), and VENT-01 (systemic NLRP3 inhibitor partnered with Novo Nordisk). The pipeline is powered by the proprietary ReSOLVE® platform, which combines AI/ML, protein science, structural biology, and biophysics for structure-based small molecule drug discovery.

Product and service5 records
1ReSOLVE® Platform
CategoryDrug Discovery Platform / Core Technology
Description

Proprietary drug discovery platform that combines AI/ML, protein science, structural biology, and biophysics to model all conformations of a protein, identify druggable pockets, analyze dynamic water networks, and generate Hydrocophore® blueprints for small molecule therapeutics targeting previously undruggable proteins. Licensed to Genentech under a multi-year discovery collaboration.

2VENT-03
CategoryClinical-stage Drug Candidate (cGAS franchise)
Description

First-in-class, oral small molecule inhibitor of cGAS (cyclic GMP-AMP synthase) currently in Phase 2 clinical trials for systemic lupus erythematosus (lupus), with expansion opportunities across immunology, inflammation, and cardiometabolic conditions including dermatomyositis and Sjögren's disease.

3VENT-02
CategoryClinical-stage Drug Candidate (NLRP3 brain franchise)
Description

Selective, brain-penetrant oral small molecule NLRP3 inhibitor in Phase 2 development for Parkinson's disease, with potential for best-in-class symptomatic relief and disease modification by addressing NLRP3-mediated neuroinflammation.

4VENT-04
CategoryPreclinical Drug Candidate (Caspase-4/5 franchise)
Description

First-in-class, oral small molecule allosteric inhibitor of caspase-4 and caspase-5 in preclinical/IND-enabling stage for inflammatory bowel disease (IBD), hidradenitis suppurativa (HS), severe asthma, and COPD.

5VENT-01
CategoryPartnered Drug Candidate (Systemic NLRP3 franchise)
Description

Oral systemic NLRP3 inhibitor in Phase 1 clinical trials, partnered exclusively with Novo Nordisk for development and commercialization of systemic NLRP3 inhibitors across multiple indications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Multi-year collaboration and license agreement to discover and develop small-molecule medicines using Ventus' ReSOLVE platform. Ventus receives upfront payment plus preclinical, development, and commercial milestones exceeding $460 million, along with tiered royalties on net sales. Genentech leads preclinical and clinical development and commercialization for targets in immunological, inflammatory, and neurological disorders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-29
Description

Exclusive development and license agreement to develop and commercialize candidates from Ventus' portfolio of systemic NLRP3 inhibitors, including VENT-01. Phase 1 clinical trial of VENT-01 is ongoing under this partnership.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining generative chemistry, target identification, and biology to advance small molecule programs in fibrosis, immunology, and oncology. Comparable to Ventus in deploying AI/ML-enabled platform for small molecule discovery.

TypeDirect peer
Description

Clinical-stage biotech developing brain-penetrant and peripheral NLRP3 inhibitors for inflammatory and neurological diseases. Direct competitor to Ventus's VENT-02 NLRP3 program in Parkinson's and to VENT-01's systemic NLRP3 franchise.

TypeBroad incumbent
Description

Large pharmaceutical company with active NLRP3 inhibitor programs (e.g., through its acquisition of IFM Tre) and broad inflammation/autoimmune franchise. Comparable as a competitor in the same NLRP3 and inflammation therapeutic space.

TypeBroad incumbent
Description

Large pharmaceutical company with multiple inflammasome and innate immunity programs, including NLRP3 and cGAS-STING pathway research. Comparable as a broad incumbent in innate immune drug discovery with overlapping therapeutic interests.

TypeEmerging player
Description

Clinical-stage immunology biotech developing antibody-based therapeutics for inflammatory and autoimmune diseases, including IL-36R and PD-1 agonist programs. Comparable as a focused inflammation biotech with partnered programs (e.g., with GSK and Roche).

TypeDirect peer
Description

AI-driven precision medicine company using its CentaurAI platform for small molecule drug design, with active programs in inflammation and immuno-oncology. Comparable to Ventus in platform-driven small molecule discovery and pharma partnership model.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology, automation, and machine learning to identify novel therapeutic candidates. Comparable to Ventus as a technology-first, platform-driven small molecule discovery company pursuing inflammatory and rare disease targets.

TypeDirect peer
Description

Computational chemistry and physics-based drug discovery platform serving both internal pipeline and pharma partnerships. Comparable to Ventus in applying physics-based modeling and computational approaches to small molecule discovery against structurally challenging targets.

TypeEmerging player
Description

Clinical-stage biotech developing molecular glue degraders for inflammation and immunology targets, including VAV1 and NEK7. Comparable as a platform-driven company pursuing previously challenging protein targets in inflammatory disease.

TypeDirect peer
Description

Clinical-stage biotech developing dapansutrile and other NLRP3 inflammasome inhibitors for inflammatory diseases including gout, cardiovascular, and autoimmune indications. Direct competitor in the systemic NLRP3 inhibitor space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ventus Therapeutics

Small Molecule Therapeuticsventustx.com

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small-molecule drugs targeting cGAS, NLRP3, and caspase-4/5 pathways for patients with autoimmune, inflammatory, and neurological diseases, powered by its proprietary ReSOLVE® AI/ML-enabled discovery platform and partnered with Novo Nordisk and Genentech.

What Ventus Therapeutics does

Ventus Therapeutics is a privately held, clinical-stage biopharmaceutical company developing small-molecule therapeutics that target innate immune system drivers of disease, specifically the cGAS, NLRP3, and caspase-4/5 pathways, across autoimmune, inflammatory, and neurological indications. The company was founded in 2020 and is headquartered in Waltham, Massachusetts with an additional research and operations footprint in Saint-Laurent (Montreal), Quebec. Its pipeline comprises VENT-03 (a first-in-class oral cGAS inhibitor in Phase 2 for lupus, with expansion plans into broader immunology and cardiometabolic disease), VENT-02 (a brain-penetrant oral NLRP3 inhibitor in Phase 2 for Parkinson's disease), VENT-01 (a systemic NLRP3 inhibitor in Phase 1, partnered with Novo Nordisk), and VENT-04 (a first-in-class allosteric caspase-4/5 inhibitor in IND-enabling studies for IBD, hidradenitis suppurativa, severe asthma, and COPD).

Discovery is powered by the proprietary ReSOLVE® platform, which combines AI/ML with protein science, structural biology, and biophysics to model full protein conformations, identify druggable pockets, characterize dynamic water networks, and generate Hydrocophore® blueprints for rapid virtual screening of billions of compounds. The platform has produced clinically validated outputs: VENT-02 demonstrated 100% IL-1β inhibition in an ex vivo whole-blood challenge assay, broad therapeutic index, and high brain penetration; VENT-03 completed Phase 1 with robust target engagement and once-daily dosing; and a $150,000 grant from The Michael J. Fox Foundation supports an NLRP3 PET tracer diagnostic program.

Ventus operates a capital-light business model with no commercial products. Revenue is generated through collaboration and licensing economics: the company has raised approximately $290 million across Series A, B, and C financings from Versant Ventures, SoftBank Vision Fund 2, RA Capital Management, GV, a16z, and others, and has secured two major strategic partnerships — an exclusive license to Novo Nordisk for systemic NLRP3 inhibitors (September 2022) and a multi-year discovery collaboration with Genentech (October 2025) carrying potential milestones exceeding $460 million plus tiered royalties. Partners lead downstream clinical development and commercialization, allowing Ventus to remain a focused, platform- and early-clinical-stage organization of 11–50 employees.

Ventus Therapeutics firmographics

Firmographics
Name
Ventus Therapeutics
Legal name
Ventus Therapeutics, Inc.
Website
https://ventustx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Ventus Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small-molecule drugs targeting cGAS, NLRP3, and caspase-4/5 pathways for patients with autoimmune, inflammatory, and neurological diseases, powered by its proprietary ReSOLVE® AI/ML-enabled discovery platform and partnered with Novo Nordisk and Genentech.
Ownership category
akta.pro rank

Where Ventus Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ventus Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Collaboration and License Agreement Revenue: Ventus receives upfront payments, preclinical, development, and commercial milestones exceeding $460 million plus tiered royalties on net sales from Genentech collaboration. The company also has a license agreement with Novo Nordisk for NLRP3 inhibitors.
  2. Partnered Program Development: VENT-01 is partnered with Novo Nordisk under exclusive development and license agreement. Ventus nominates development candidates which are then developed and commercialized by partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Ventus Therapeutics product offering

Product offering

Core offering

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of differentiated small molecule therapeutics targeting biologically validated but previously undruggable drug targets in innate immunity. Its lead candidates include VENT-03 (cGAS inhibitor, Phase 2 for lupus), VENT-02 (NLRP3 inhibitor, Phase 2 for Parkinson's disease), VENT-04 (caspase-4/5 inhibitor, preclinical), and VENT-01 (systemic NLRP3 inhibitor partnered with Novo Nordisk). The company monetizes through upfront payments, development milestones, and royalties via partnerships with Genentech and Novo Nordisk, using its proprietary ReSOLVE® platform for discovery.

Product overview

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of differentiated small molecule therapeutics targeting biologically validated but previously considered undruggable drug targets in immunology, inflammation, and neurology. The company's portfolio includes: VENT-03 (first-in-class cGAS inhibitor in Phase 2 for lupus), VENT-02 (brain-penetrant NLRP3 inhibitor in Phase 2 for Parkinson's disease), VENT-04 (first-in-class caspase-4/5 inhibitor in preclinical development for IBD, HS, asthma, and COPD), and VENT-01 (systemic NLRP3 inhibitor partnered with Novo Nordisk). The pipeline is powered by the proprietary ReSOLVE® platform, which combines AI/ML, protein science, structural biology, and biophysics for structure-based small molecule drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • ReSOLVE® Platform Proprietary drug discovery platform that combines AI/ML, protein science, structural biology, and biophysics to model all conformations of a protein, identify druggable pockets, analyze dynamic water networks, and generate Hydrocophore® blueprints for small molecule therapeutics targeting previously undruggable proteins. Licensed to Genentech under a multi-year discovery collaboration.
  • VENT-03 First-in-class, oral small molecule inhibitor of cGAS (cyclic GMP-AMP synthase) currently in Phase 2 clinical trials for systemic lupus erythematosus (lupus), with expansion opportunities across immunology, inflammation, and cardiometabolic conditions including dermatomyositis and Sjögren's disease.
  • VENT-02 Selective, brain-penetrant oral small molecule NLRP3 inhibitor in Phase 2 development for Parkinson's disease, with potential for best-in-class symptomatic relief and disease modification by addressing NLRP3-mediated neuroinflammation.
  • VENT-04 First-in-class, oral small molecule allosteric inhibitor of caspase-4 and caspase-5 in preclinical/IND-enabling stage for inflammatory bowel disease (IBD), hidradenitis suppurativa (HS), severe asthma, and COPD.
  • VENT-01 Oral systemic NLRP3 inhibitor in Phase 1 clinical trials, partnered exclusively with Novo Nordisk for development and commercialization of systemic NLRP3 inhibitors across multiple indications.

Quantifiable outcome

  • VENT-02 demonstrated 100% inhibition of IL-1β in blood in ex vivo whole blood challenge assay
  • +2 more outcomes

Companies that use Ventus Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Ventus Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ventus Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • GenentechcoreStrategic or Co-development Partner · 21 October 2025Multi-year collaboration and license agreement to discover and develop small-molecule medicines using Ventus' ReSOLVE platform. Ventus receives upfront payment plus preclinical, development, and commercial milestones exceeding $460 million, along with tiered royalties on net sales. Genentech leads preclinical and clinical development and commercialization for targets in immunological, inflammatory, and neurological disorders.
  • Novo NordiskcoreStrategic or Co-development Partner · 29 September 2022Exclusive development and license agreement to develop and commercialize candidates from Ventus' portfolio of systemic NLRP3 inhibitors, including VENT-01. Phase 1 clinical trial of VENT-01 is ongoing under this partnership.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Ventus Therapeutics competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and biology to advance small molecule programs in fibrosis, immunology, and oncology. Comparable to Ventus in deploying AI/ML-enabled platform for small molecule discovery.
  • NodThera: Clinical-stage biotech developing brain-penetrant and peripheral NLRP3 inhibitors for inflammatory and neurological diseases. Direct competitor to Ventus's VENT-02 NLRP3 program in Parkinson's and to VENT-01's systemic NLRP3 franchise.
  • Exscientia: AI-driven precision medicine company using its CentaurAI platform for small molecule drug design, with active programs in inflammation and immuno-oncology. Comparable to Ventus in platform-driven small molecule discovery and pharma partnership model.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology, automation, and machine learning to identify novel therapeutic candidates. Comparable to Ventus as a technology-first, platform-driven small molecule discovery company pursuing inflammatory and rare disease targets.
  • Schrödinger: Computational chemistry and physics-based drug discovery platform serving both internal pipeline and pharma partnerships. Comparable to Ventus in applying physics-based modeling and computational approaches to small molecule discovery against structurally challenging targets.
  • Olatec Therapeutics: Clinical-stage biotech developing dapansutrile and other NLRP3 inflammasome inhibitors for inflammatory diseases including gout, cardiovascular, and autoimmune indications. Direct competitor in the systemic NLRP3 inhibitor space.

Broad incumbents

  • Novartis: Large pharmaceutical company with active NLRP3 inhibitor programs (e.g., through its acquisition of IFM Tre) and broad inflammation/autoimmune franchise. Comparable as a competitor in the same NLRP3 and inflammation therapeutic space.
  • AstraZeneca: Large pharmaceutical company with multiple inflammasome and innate immunity programs, including NLRP3 and cGAS-STING pathway research. Comparable as a broad incumbent in innate immune drug discovery with overlapping therapeutic interests.

Emerging players

  • AnaptysBio: Clinical-stage immunology biotech developing antibody-based therapeutics for inflammatory and autoimmune diseases, including IL-36R and PD-1 agonist programs. Comparable as a focused inflammation biotech with partnered programs (e.g., with GSK and Roche).
  • Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders for inflammation and immunology targets, including VAV1 and NEK7. Comparable as a platform-driven company pursuing previously challenging protein targets in inflammatory disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Ventus Therapeutics social profiles

Digital presence

Ventus Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ventus Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Ventus Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ventus Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventus Therapeutics

What does Ventus Therapeutics do?

Ventus Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of differentiated small molecule therapeutics targeting biologically validated but previously undruggable drug targets in innate immunity. Its lead candidates include VENT-03 (cGAS inhibitor, Phase 2 for lupus), VENT-02 (NLRP3 inhibitor, Phase 2 for Parkinson's disease), VENT-04 (caspase-4/5 inhibitor, preclinical), and VENT-01 (systemic NLRP3 inhibitor partnered with Novo Nordisk). The company monetizes through upfront payments, development milestones, and royalties via partnerships with Genentech and Novo Nordisk, using its proprietary ReSOLVE® platform for discovery.

Is Ventus Therapeutics a public or private company?

Ventus Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ventus Therapeutics founded?

Ventus Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Ventus Therapeutics based?

Ventus Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Ventus Therapeutics make money?

Two revenue lines are on record. Collaboration and License Agreement Revenue is the primary driver. The others are partnered Program Development.

Who are Ventus Therapeutics's main competitors?

Direct peers on record are Insilico Medicine, NodThera, Exscientia, Recursion Pharmaceuticals, Schrödinger and Olatec Therapeutics. Broad incumbents are Novartis and AstraZeneca. Emerging players are AnaptysBio and Monte Rosa Therapeutics.

Does Ventus Therapeutics have an API?

No public API is recorded for Ventus Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VentustxVentus TherapeuticsVentus Therapeutics has nominated VENT-04 as its lead development candidate, describing it as a first-in-class, oral small-molecule inhibitor of caspase-4 and -5. The compound utilizes the company's proprietary ReSOLVE platform to target autoimmune diseases characterized by bacteria-mediated barrier disruption, such as inflammatory bowel disease and hidradenitis suppurativa.BioSpaceVentus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with LupusVentus Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of VENT-03, an oral small-molecule cGAS inhibitor for lupus patients. VENT-03 is the first oral small-molecule cGAS inhibitor to advance from a completed first-in-human Phase 1 study into Phase 2 development. Top-line results from the 28-day placebo-controlled portion of the trial are expected in the second half of 2026.Business Wire BlogVentus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with LupusVentus Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of VENT-03, an oral small-molecule cGAS inhibitor for lupus, making it the first cGAS inhibitor to advance from Phase 1 to Phase 2. The multicenter, randomized, double-blind trial will evaluate safety and efficacy in lupus patients with active skin disease, measuring changes in interferon-stimulated gene signatures and inflammatory markers, with top-line data expected in the second half of 2026. The company highlighted that VENT-03 has expansion potential beyond lupus into other interferon-driven immunological and inflammatory diseases, cardiometabolic disorders, and inflammaging.Endpoints NewsVentus stops Phase 2 of NLRP3 inhibitor that was being tested in Parkinson’sVentus Therapeutics has terminated the Phase 2a clinical trial of its NLRP3 inhibitor, which was being investigated for the treatment of Parkinson’s disease. This decision halts development of a compound from a prominent drug class with broad potential in neurology.BioSpaceVentus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus’ ReSOLVE® PlatformVentus Therapeutics has entered into a multi-year collaboration and license agreement with Genentech to discover and develop small-molecule medicines using Ventus' proprietary ReSOLVE® drug discovery platform, with Genentech handling subsequent preclinical development, clinical development, and commercialization. Ventus will receive an upfront payment and is eligible for preclinical, development, and commercial milestones exceeding $460 million plus tiered royalties on net sales. The collaboration aims to address challenging therapeutic targets in major disease areas by leveraging ReSOLVE's AI/ML-enabled approach to model water networks in protein pockets and generate novel small-molecule candidates.VentustxVentus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus’ ReSOLVE® PlatformVentus Therapeutics announced a multi-year collaboration and license agreement with Genentech to discover and develop small-molecule medicines using Ventus' proprietary ReSOLVE® platform, which combines AI, machine learning, and structural biology to model protein water networks for drug discovery. Under the terms, Ventus will receive an upfront payment plus preclinical, development, and commercial milestones exceeding $460 million, along with tiered royalties on net sales, while Genentech will lead preclinical and clinical development and commercialization. The collaboration positions Genentech, a member of the Roche Group, to access Ventus' computational approach for addressing challenging therapeutic targets in immunological, inflammatory, and neurological disorders.Business Wire BlogVentus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS InhibitorVentus Therapeutics completed its Phase 1 trial of VENT-03, a first-in-class oral cGAS inhibitor, in 72 healthy volunteers. The drug was safe and well-tolerated, with no serious adverse events, and showed favorable pharmacokinetics supporting once-daily dosing. Ventus plans to initiate a Phase 2 trial in lupus in 2025.Business Wire BlogVentus Therapeutics Significantly Expands its Presence in Montreal, Canada with Opening of a New Laboratory and Office FacilityVentus Therapeutics opened a new 24,000-square-foot laboratory and office facility in Montreal, Canada, more than doubling its Montreal space. The facility will support its R&D capacity and further development of its ReSOLVE™ platform, which has enabled three clinical-stage compounds.VentustxVentus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo NordiskNovo Nordisk has dosed the first participant in a Phase 1 clinical study for NNC6022-0001, an oral NLRP3 inhibitor exclusively licensed from Ventus Therapeutics. The trial aims to evaluate the drug's pharmacokinetics, safety, and efficacy in healthy volunteers for potential treatment of cardiometabolic diseases. This milestone marks the third compound discovered by Ventus to enter clinical development within nine months.